Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, August 19 at 2:00 PM EDT

Register Free →

Search

Top

A&G Pharmaceutical, Inc. 9130 Red Branch Rd., STE U COLUMBIA MD 21045 USA

UEI: SLED_84C4D9CC9D8E138F

A&G Pharmaceutical, Inc. 9130 Red Branch Rd., STE U COLUMBIA MD 21045 USA is a federal contractor, registered under UEI SLED_84C4D9CC9D8E138F. It has been awarded $353,400 across 1 federal contract. Primary work spans Research and Development in Biotechnology.

Contact Information

Registration and classification details

Registration

UEI Code

SLED_84C4D9CC9D8E138F

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

Key Performance Metrics

Awards Count

0

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency

$353.4K100%

Awards by NAICS

541711 - Research and Development in Biotechnology$353.4K100%

Awards by Agency Over Time

Awards by Place of Performance

Open opportunities in A&G Pharmaceutical, Inc. 9130 Red Branch Rd., STE U COLUMBIA MD 21045 USA's top NAICS codes and agencies

Technical Data Acquisition & Reverse Engineering

Ok DLA Aviation At Oklahoma City

POSTED

DEADLINE

Data Collection & Analytics for Lunar MissionsThe National Aeronautics And Space Administration, specifically the Space Operations Mission Directorate, is seeking a subcontractor to develop data collection frameworks and analytical models focused on health metrics. This initiative is designed to monitor and analyze astronaut health during lunar missions ranging from short-duration stays to month-long deployments. The opportunity was posted on August 11, 2026, with a response deadline of September 8, 2026. Classified under NAICS code 541711, the project emphasizes the creation of robust systems to ensure the well-being of crew members during extended lunar operations.

Space Operations Mission Directorate

POSTED

DEADLINE

Pharmaceutical-Based Agent (PBA) Detection Systems

POSTED

DEADLINE

Dose Formulation and Compound Handling

National Institutes Of Health Olao

POSTED

DEADLINE

Integrated Phase I/II Clinical Trial DesignThe contract seeks the design and protocol development for an integrated Phase I/II clinical trial to evaluate ibogaine as a potential treatment for opioid use disorder, focusing on safety, optimal dosing, and therapeutic efficacy. The effort requires a comprehensive clinical framework that seamlessly merges the objectives of Phase I, which prioritizes dose escalation and toxicity profiling, with those of Phase II, which assesses preliminary effectiveness in reducing opioid dependence and withdrawal symptoms. The protocol must adhere to rigorous scientific and regulatory standards, incorporating appropriate patient selection criteria, monitoring procedures, endpoints, and risk mitigation strategies for a substance with significant pharmacological and safety considerations. The work is being pursued as a subcontract under the Advanced Research Projects Agency for Health, part of the Department of Health and Human Services, with a NAICS code indicating research and development in the life sciences. The solicitation was posted on August 5, 2026, and responses are due by October 15, 2026. The project is situated within a broader initiative to advance novel therapeutic interventions for the opioid crisis, requiring innovative trial design that balances exploratory research with clinical feasibility. There is no specified set-aside designation or location restriction for performance, indicating flexibility in execution while emphasizing scientific merit and regulatory alignment as key evaluation criteria.

Advanced Research Projects Agency For Health (arpa-H)

POSTED

DEADLINE

Phage-Based Formulation Development

W6QK Acc Ccdc Sttc

POSTED

DEADLINE

High-Throughput Yeast Two-Hybrid ScreeningA large-scale yeast two-hybrid screening project is being sought to identify protein-protein interactions between viral bait proteins and aphid prey libraries, encompassing all necessary laboratory procedures including yeast transformation and interaction assays. The effort is designed to enable high-throughput discovery of molecular connections critical to understanding viral infection dynamics in aphid hosts, with the goal of advancing agricultural pest and disease control strategies. This subcontract is designated as a Small Business Set Aside under NAICS code 541711, reserved exclusively for small business concerns, and is managed by the USDA Agricultural Research Service through its Albany Facility. The opportunity was posted on August 4, 2026, with a firm response deadline of August 28, 2026, and the performance location is specified as Ithaca, New York, with a zip code of 14853. The contract type and set-aside status emphasize support for small business participation in federally funded scientific research aimed at improving agricultural outcomes.

USDA Ars Afm Apd

POSTED

DEADLINE

Aphid cDNA Prey Library DevelopmentThe contract involves the development of a normalized cDNA library from aphid RNA supplied by the government, specifically for use in yeast two-hybrid prey systems. The work includes reverse transcription of the RNA into complementary DNA and subsequent cloning procedures to generate a high-quality, representative library that enables effective protein-protein interaction screening. The project is designed to support biological research efforts by providing a standardized, scalable prey library that enhances the reliability and depth of interaction data in functional genomics studies. This subcontract is designated as a Small Business Set Aside under the NAICS code 541711, indicating it is reserved for small businesses engaged in research and development in the life sciences. The work is to be performed in Ithaca, New York, with a response deadline of August 28, 2026, and was posted on August 4, 2026. The contracting entity is the USDA Agricultural Research Service, Agricultural Facilities Management and Application Personnel Division, and the project is intended to advance USDA’s mission in agricultural biotechnology and pest research through innovative molecular tools.

USDA Ars Afm Apd

POSTED

DEADLINE

Viral Bait Clone ConstructionThe contract involves the design and molecular cloning of viral protein bait constructs specifically for use in yeast two-hybrid systems, requiring comprehensive molecular biology expertise including codon optimization for host compatibility, precise plasmid insertion, and rigorous sequence validation to ensure accuracy and functionality. The work focuses on creating reliable protein baits that enable the study of virus-host protein interactions, which is critical for understanding pathogenic mechanisms and identifying potential therapeutic targets. All constructs must meet high standards of precision to support downstream functional assays in a controlled laboratory environment. The contract is designated as a Small Business Set Aside under NAICS code 541711 for scientific research and development, with performance to be carried out in Ithaca, New York, at the USDA ARS AFM APD facility. It was posted on August 4, 2026, and responses are due by August 28, 2026, with a clear emphasis on delivering technically robust and validated molecular reagents within the specified timeframe. The scope demands a high level of technical proficiency in molecular cloning, sequence analysis, and bioinformatics tools, with deliverables expected to support ongoing virology and host-pathogen interaction research funded by the U.S. Department of Agriculture.

USDA Ars Afm Apd

POSTED

DEADLINE

In Vitro ADMET AssaysThe contract titled In Vitro ADMET Assays calls for the performance of high-throughput in vitro screening focused on metabolic stability, hepatotoxicity, CYP450 enzyme interactions, and cellular permeability to support early-stage drug development. These assays are critical for evaluating the absorption, distribution, metabolism, excretion, and toxicity profiles of potential therapeutic candidates, enabling informed decisions before advancing compounds into costly clinical stages. The work will be conducted to meet the specific needs of the National Institutes of Health NIDA under the Department of Health and Human Services, with performance expected to occur in Bethesda. This is a subcontract opportunity under NAICS code 541711, which classifies it as research and development in the physical, engineering, and life sciences. The solicitation was posted on August 3, 2026, with a response deadline of August 18, 2026, at 7:00 PM Eastern Time. There is no set-aside classification specified, and no point of contact or detailed office address is provided in the data. Interested parties must submit their proposals before the deadline to be considered for award, with the expectation that the selected contractor will deliver reliable, scalable, and scientifically rigorous ADMET data to guide NIDA’s research initiatives in drug development.

National Institutes Of Health Nida

POSTED

DEADLINE

Genotoxicity and Carcinogenicity TestingThe contract seeks to perform in vitro and in vivo assays to assess the mutagenic and carcinogenic risks of drug candidates, ensuring compliance with regulatory safety standards for pharmaceutical development. The work is critical for identifying potential genetic toxicity and cancer-causing properties early in the drug evaluation process to support regulatory submissions and public health safeguards. The solicitation is issued as a subcontract under the National Institutes of Health NIDA, part of the Department of Health and Human Services, with performance expected to take place in Bethesda. It falls under the NAICS code 541711 for research and development in the physical, engineering, and life sciences. The proposal must be submitted by August 18, 2026, with the opportunity posted on August 3, 2026. No set-aside provisions are specified, and the contract is open to qualified subcontractors with the technical capacity to deliver high-quality genotoxicity and carcinogenicity testing services.

National Institutes Of Health Nida

POSTED

DEADLINE

Safety Pharmacology (CNS, Cardiovascular, Pulmonary)The contract requires comprehensive safety pharmacology studies to evaluate adverse effects on the central nervous system, cardiovascular system, and pulmonary function, ensuring alignment with ICH safety guidelines. The work will involve detailed pharmacodynamic assessments to identify and characterize potential risks to major organ systems during early drug development, with a focus on identifying safety signals that could impact clinical translation. This subcontract, issued by the National Institutes of Health’s NIDA under the Department of Health and Human Services, is set to be performed in Bethesda and has a response deadline of August 18, 2026. The effort is classified under NAICS code 541711, indicating it pertains to research and development in the life sciences, and is aimed at supporting regulatory-compliant preclinical safety evaluations essential for pharmaceutical advancement.

National Institutes Of Health Nida

POSTED

DEADLINE

Toxicity Testing (Acute, Subacute, Subchronic, Chronic)The contract requires the performance of comprehensive toxicity testing in both rodent and non-rodent models to assess organ toxicity and establish safety margins for submission to regulatory authorities as part of an Investigational New Drug application. The scope includes acute, subacute, subchronic, and chronic studies designed to evaluate the potential adverse effects of pharmaceutical compounds across a range of exposure durations and dosages. The work must meet rigorous scientific standards to support regulatory filings and ensure the safety profile of investigational drugs is adequately characterized prior to human trials. This subcontract is issued under the National Institutes of Health, National Institute on Drug Abuse, within the Department of Health and Human Services, with the performance location specified as Bethesda. The North American Industry Classification System code 541711 identifies the work as research and development in the life sciences. The solicitation was posted on August 3, 2026, with a mandatory response deadline of August 18, 2026, at 7:00 PM. No set-aside provisions are specified, and the contract opportunity is open to eligible contractors capable of executing preclinical toxicology studies to support IND submissions.

National Institutes Of Health Nida

POSTED

DEADLINE

In Vivo Pharmacokinetic StudiesThe contract seeks to perform in vivo pharmacokinetic studies to assess the absorption, distribution, metabolism, and excretion of a drug candidate in both rodent and non-rodent species across multiple administration routes, with the goal of generating data to support an Investigational New Drug application. These studies will evaluate drug exposure over time to establish pharmacokinetic profiles critical for regulatory submission, requiring rigorous experimental design, appropriate species selection, and adherence to good laboratory practices. All work must be completed to ensure high-quality, reproducible results that meet FDA expectations for preclinical development. The solicitation is classified as a subcontract under NAICS code 541711, issued by the National Institutes of Health through the National Institute on Drug Abuse, part of the Department of Health and Human Services. Performance is expected to take place in Bethesda, and interested parties must submit their responses no later than August 18, 2026, at 7:00 PM. The opportunity was posted on August 3, 2026, and is open for competitive bidding with no specific set-aside designation. The contract does not provide a point of contact, and all inquiries must be directed through the official SAM.gov portal linked in the posting.

National Institutes Of Health Nida

POSTED

DEADLINE

Clinical Trial Design and Efficacy Data GenerationThe contract calls for the design and execution of clinical trials aimed at evaluating the safety, wound closure, infection control, and functional regeneration outcomes of medical interventions in patients with burn and trauma injuries. The work requires rigorous scientific methodology to generate robust efficacy data that supports regulatory and clinical adoption, with a focus on measurable endpoints related to tissue recovery and patient outcomes. The trials must be conducted in accordance with established clinical standards and are intended to provide evidence of therapeutic effectiveness under real-world conditions. This is a subcontract under the Aspr Administration for Strategic Preparedness and Response, part of the Department of Health and Human Services, with a solicitation posted on July 28, 2026, and a response deadline of August 28, 2026. The work is classified under NAICS code 541711, indicating research and development in the life sciences. The performance location is designated with a zip code of 77416, though no specific city or state is provided, and no point of contact details are listed. The contract does not include a set-aside designation, and all eligible entities may respond, with emphasis placed on technical capability, trial design expertise, and experience in trauma and burn clinical research.

Aspr Administration For Strategic Preparedness And Response

POSTED

DEADLINE

Preclinical Animal Studies for Neurofibromatosis ResearchThe contract seeks to conduct preclinical in vivo studies using genetically engineered mouse models or alternative animal models of neurofibromatosis to assess the efficacy of therapeutic interventions, track tumor progression, and investigate underlying biological mechanisms. The work requires advanced expertise in animal modeling, tumor biology, and preclinical drug evaluation, with a focus on generating robust, reproducible data to support future clinical translation. All studies must be conducted in accordance with established ethical and scientific standards for animal research, with detailed documentation of methodologies, outcomes, and adverse events. This subcontract is issued under the Defense Health Agency Contracting Activity and falls under NAICS code 541711, indicating it supports research and development in the physical, engineering, and life sciences. The solicitation was posted on June 25, 2026, with a response deadline of September 22, 2026, and is open to qualified entities capable of executing complex preclinical studies. While the place of performance and point of contact details are unspecified, successful proposers must demonstrate capacity to manage animal facilities, comply with regulatory requirements, and deliver high-quality, timely results in support of neurofibromatosis research objectives under the Department of Defense.

Defense Health Agency Contracting Activity - Dhaca

POSTED

about 2 months ago

DEADLINE

in about 1 month

Collaborative Biomedical Research ExecutionThis contract enables a collaborative biomedical research effort focused on neurofibromatosis, requiring coordinated hypothesis-driven investigations led by an Initiating Principal Investigator and a Partnering Principal Investigator. The work encompasses the design of experiments, generation of empirical data, and rigorous milestone-based progress reporting to ensure scientific rigor and accountability. The project is structured as a subcontract under the Defense Health Agency Contracting Activity, falling under the NAICS code for research and development in the physical, engineering, and life sciences, and is intended to advance understanding of neurofibromatosis through integrated scientific contributions. The solicitation was posted on June 25, 2026, with a response deadline of September 22, 2026, and is managed by the Department of Defense through its health research infrastructure. While no set-aside provisions or specific location details are provided, the emphasis is firmly on outcome-driven research with clearly defined deliverables tied to research milestones. The effort requires close alignment between the two principal investigators to ensure cohesive experimental planning, data integrity, and timely reporting, reflecting a strategic investment in translational medical science with potential implications for defense-relevant health conditions.

Defense Health Agency Contracting Activity - Dhaca

POSTED

about 2 months ago

DEADLINE

in about 1 month

Collaborative Research Partnership (Partnering PI Option)This contract establishes a collaborative research partnership where a Partnering Principal Investigator from an external institution will co-lead the research effort alongside the primary team, sharing equal responsibility for scientific direction, project management, and deliverables. Funding is jointly allocated between the participating institutions, ensuring aligned resources and mutual accountability for outcomes, with the work focused on health-related research under the Defense Health Agency Contracting Activity. The initiative falls under NAICS code 541711, indicating it is within the scientific research and development sector, and is structured as a subcontract to support integrated, multi-institutional innovation. The opportunity was posted on June 18, 2026, with a deadline for responses set for September 28, 2026, providing potential partners a defined window to submit proposals. The partnership is expected to be conducted in alignment with the mission of the Department of Defense, addressing critical health priorities through joint scientific leadership. There is no set-aside designation specified, meaning eligibility is open to qualified institutions regardless of size or status, and no specific location is designated for performance, allowing flexibility in where the research activities are carried out as long as the objectives are met collaboratively.

Defense Health Agency Contracting Activity - Dhaca

POSTED

about 2 months ago

DEADLINE

in about 1 month